Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
– Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD).
Recent Comments